Swiss biopharma firm ObsEva SA, specializing in women's health and IVF, announces the departure of Dr. Catarina Edfjäll from its Board and the decision to wind down operations.
ObsEva SA, a Swiss biopharma firm specializing in women's health, announces Dr. Catarina Edfjäll's departure from its Board of Directors, coinciding with the company's decision to wind down operations. Dr. Edfjäll's contributions to ObsEva are appreciated, and the company wishes her success in future ventures. ObsEva, listed on SIX Swiss Exchange (OBSN), focuses on improving IVF success rates.
March 19, 2024
3 Articles